Bio News
Researchers at Stanford University School of Medicine designed TCIP3, a bifunctional molecule that converts BCL6, a protein that drives B-cell lymphoma, into a molecule that induces cell death. TCIP3 physically linked BCL6 with P300 or CBP, proteins that add acetyl marks, promoting the expression of cell-death genes. The researchers administered it twice daily to mice implanted with human lymphoma cells and completely eliminated the tumors in 11 days.
Biobook Team
biobookmedia@biobook.co.krRoche’s New Drug for Uveitic Macular Edema Faces FDA Decision in July 2027
BMS Reports Concurrent Phase 3 Success in Idiopathic Pulmonary Fibrosis and Solid Tumors
Merck’s $1.3 trillion eye disease drug raises safety and efficacy concerns: “Limited competitiveness”
CHA Biotech Holds 24.23% Stake in CMG Pharmaceutical as Share Consolidation Reduces Its Share Count
Rural Development Administration Develops Two Molecular Markers to Identify Leaf Splitting in Squash
MFDS Begins Distribution of Internationally Certified Reference Materials, Including 24 New Items, for a Total of 882
